ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    THE FUNCTION AND FATE OF TRANSFUSED LEUKOCYTES FROM DONORS WITH CHRONIC MYELOCYTIC LEUKEMIA IN LEUKOPENIC RECIPIENTS (1964)
    Oxford, UK : Blackwell Publishing Ltd
    Annals of the New York Academy of Sciences 113 (1964), S. 0 
    Details
    ISSN: 1749-6632
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Natural Sciences in General
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1749-6632.1964.tb40726.x
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Importance of Bulk Flow in the Exchange of Compounds across the Blood Cerebrospinal Fluid Barrier (1962)
    [s.l.] : Nature Publishing Group
    Nature 193 (1962), S. 383-385 
    Details
    ISSN: 1476-4687
    Source: Nature Archives 1869 - 2009
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Notes: [Auszug] Drugs insoluble in lipid and with large molecules were used, and their rate of entrance, the steady-state ratio of concentration of drug in cerebrospinal fluid/ drug in plasma and rate of exit from cerebrospinal fluid in dogs were investigated. Inulin (molecular weight 5,000, New England Nuclear ...
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1038/193383a0
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Ethical Considerations in Cancer Chemotherapy (1979)
    Palo Alto, Calif. : Annual Reviews
    Annual Review of Pharmacology 19 (1979), S. 547-557 
    Details
    ISSN: 0362-1642
    Source: Annual Reviews Electronic Back Volume Collection 1932-2001ff
    Topics: Medicine , Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1146/annurev.pa.19.040179.002555
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Phase I evaluation of intravenous difluoromethylornithine — a polyamine inhibitor (1985)
    Springer
    Investigational new drugs 3 (1985), S. 287-292 
    Details
    ISSN: 1573-0646
    Keywords: difluoromethylornithine ; phase I ; leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Difluoromethylornithine (DFMO), a non-competitive inhibitor of ornithine decarboxylase (ODC), the rate limiting enzyme of the polyamine synthetic pathway was evaluated in a Phase I trial. Intravenous DFMO was given to twenty patients with refractory leukemia by continuous infusion in doses from 5.5 to 64 g/m2. Toxicity clearly attributable to the drug was not severe and other than nausea and vomiting did not increase with dose. The previously reported ototoxicity which occurred with the oral form appeared to be less frequent. Loss of hearing which improved when the drug was stopped was seen in four patients, three of whom were simultaneously receiving aminoglycosides. Anorexia occurred in some patients at all doses. Vomiting, necessitating dosage reduction, was a significant problem at the highest dose administered. No patient achieved a remission but there was stabilization or decrease in circulating blast cells in several patients. This growth inhibition did not appear to be dosage related.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00179433
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    facet.materialart.
    Unknown
    Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy (1998)
    American Society of Hematology
    Details
    Publication Date: 1998-08-15
    Description: One hundred seventy-four patients with progressive or advanced chronic lymphocytic leukemia (CLL) have received initial therapy with fludarabine as a single agent or fludarabine combined with prednisone. The overall response rate was 78% and the median survival was 63 months. No difference in response rate or survival was noted in the 71 patients receiving fludarabine as a single agent compared with the 103 patients who received prednisone in addition. The median time to progression of responders was 31 months and the overall median survival was 74 months. Patients over the age of 70 years had shorter survivals. Patients with advanced stage disease (Rai III and IV) had a somewhat shorter survival than earlier stage patients. More than half the patients who relapsed after fludarabine therapy responded to salvage treatment, usually with fludarabine-based regimens. Second remissions were more common in patients who had achieved a complete remission on their initial treatment. The CD4 and CD8 T-lymphocyte subpopulations decreased to levels in the range of 150 to 200/μL after the first 3 courses of treatment. Although recovery towards normal levels was slow, the incidence of infections was low in patients in remission (1 episode of infection for every 3.33 patient years at risk) and decreased with time off treatment. There was no association of infections or febrile episodes with the use of corticosteroids or the CD4 count at the end of treatment and a poor correlation with the increase in CD4 counts during remission. Infectious episodes were less common in patients who had a complete response compared with partial responders. Richter’s transformation occurred in 9 patients and Hodgkin’s disease occurred in 4 patients. Five other patients died from other second malignancies. Fludarabine appears to be an effective initial induction therapy with a reasonable safety profile for patients with CLL. © 1998 by The American Society of Hematology.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 6
    facet.materialart.
    Unknown
    Effect of Platelets Stored at 22° C for 24 Hours in Patients With Acute Leukemia (1973)
    American Society of Hematology
    Details
    Publication Date: 1973-10-01
    Description: We have compared the ability of transfused platelets that were fresh or stored for 24 hr at room temperature (22° C) to increase the platelet counts of thrombocytopenic patients with acute leukemia. Increments in the recipients’ platelet counts after transfusion of stored platelets were substantially smaller and shorter-lived than those given by fresh platelets. This was the case even in patients who responded consistently to fresh platelets.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 7
    facet.materialart.
    Unknown
    Cytogenetic Studies in Acute Myelocytic Leukemia with Special Emphasis on the Occurrence of Ph1 Chromosome (1970)
    American Society of Hematology
    Details
    Publication Date: 1970-10-01
    Description: Cytogenetic studies were carried out on 103 unselected patients with acute myelogenous leukemia (AML) at the Clinical Center of the National Institutes of Health. Seventy-three patients (70.9%) had a normal karyotype and 30 patients (29.1%) were aneuploid. No unique chromosomal abnormalities were found in patients with aneuploidy; however, there was a significantly higher incidence of G group involvement. Four cases had a history of radiation exposure; three of these four patients had a normal karyotype and one had one Ph1 chromosome in her bone marrow cells. Another patient with no history of radiation also had one Ph1 chromosome in his marrow cells. Reclassification of AML patients with Ph1 chromosomes as a rare entity of blast crisis in chronic myelogenous leukemia (CML) rather than as AML’s is proposed. Two patients exhibited the 45 chromosome syndrome before the diagnosis of AML was made. The normal and aneuploid groups had about the same median survival time and same median date from diagnosis to chromosome study; however, none of the patients in the aneuploid group lived longer than 26 months after the date of diagnosis, while seven patients (nearly 10%) in the normal group did so, one living over 112 months.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 8
    facet.materialart.
    Unknown
    Leukapheresis Therapy of Chronic Lymphocytic Leukemia (1972)
    American Society of Hematology
    Details
    Publication Date: 1972-02-01
    Description: The effects of repeated leukapheresis with the IBM Blood Cell Separator were assessed in 13 patients with chronic lymphocytic leukemia (CLL). Five patients had from 14 to 25 leukaphereses at intervals ranging from 7 to 33 days. The median total number of lymphocytes removed was 18.0 x 1011 (range 11.9 x 1011-26.6 x 1011). Two of these patients had a decrease in lymphocyte count and in lymphadenopathy. One of the above and eight additional patients had intensive leukapheresis therapy consisting of five procedures per week for 1-4 wk. The median total number of lymphocytes removed from these patients was 11.34 x 1011 (range 3.30 x 1011-47.4 x 1011). Eight of these patients had a decrease in lymphocyte count, five in spleen size, eight in lymph node size, seven in bone marrow infiltration, and one in liver size. Lymphocyte counts before beginning leukapheresis therapy ranged from 20,500 to 684,000 (median 70,900). The median lymphocyte count on completion of treatment was 19,200 (range 6,590-40,000). After leukapheresis therapy, the median doubling time of the lymphocyte count was 71 days (range 29-118 days). In addition to demonstrating a significant proliferative component in CLL, the objective regression of disease in ten of the 13 patients suggests that leukapheresis is a potentially useful treatment for CLL.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 9
    facet.materialart.
    Unknown
    Biological Effects of Repeated Leukapheresis of Patients With Chronic Myelogenous Leukemia (1973)
    American Society of Hematology
    Details
    Publication Date: 1973-12-01
    Description: Fifteen patients with chronic myelogenous leukemia were managed only with repeated leukapheresis for up to 26 mo. At each procedure approximately 10 liters of blood were processed with a continuous-flow blood cell separator over a 3-hr period. Five patients had intermittent leukapheresis (1-2 procedures/wk), and ten of them had one or more series of intensive leukapheresis (4-5 procedures/wk). Addition of hydroxyethyl starch to the extracorporeal circuit was found to increase the removal of leukocytes fourfold. With intensive leukapheresis the leukocyte count decreased 80%, and the platelet count decreased 54% (mean values). With intermittent leukapheresis the corresponding figures were 70% and 35%. Thrombocytopenia was never clinically significant. All 15 patients experienced symptomatic improvement, and those with organomegaly had decrease in the size of the spleen and liver. Leukapheresis was not associated with morbidity, except that anemia became more severe and required periodic transfusions of packed red blood cells. Patients managed with leukapheresis did not enter bone marrow remission, and transformation of CML into blastic crisis was not prevented or delayed.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 10
    facet.materialart.
    Unknown
    Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy (1998)
    American Society of Hematology
    Details
    Publication Date: 1998-08-15
    Description: One hundred seventy-four patients with progressive or advanced chronic lymphocytic leukemia (CLL) have received initial therapy with fludarabine as a single agent or fludarabine combined with prednisone. The overall response rate was 78% and the median survival was 63 months. No difference in response rate or survival was noted in the 71 patients receiving fludarabine as a single agent compared with the 103 patients who received prednisone in addition. The median time to progression of responders was 31 months and the overall median survival was 74 months. Patients over the age of 70 years had shorter survivals. Patients with advanced stage disease (Rai III and IV) had a somewhat shorter survival than earlier stage patients. More than half the patients who relapsed after fludarabine therapy responded to salvage treatment, usually with fludarabine-based regimens. Second remissions were more common in patients who had achieved a complete remission on their initial treatment. The CD4 and CD8 T-lymphocyte subpopulations decreased to levels in the range of 150 to 200/μL after the first 3 courses of treatment. Although recovery towards normal levels was slow, the incidence of infections was low in patients in remission (1 episode of infection for every 3.33 patient years at risk) and decreased with time off treatment. There was no association of infections or febrile episodes with the use of corticosteroids or the CD4 count at the end of treatment and a poor correlation with the increase in CD4 counts during remission. Infectious episodes were less common in patients who had a complete response compared with partial responders. Richter’s transformation occurred in 9 patients and Hodgkin’s disease occurred in 4 patients. Five other patients died from other second malignancies. Fludarabine appears to be an effective initial induction therapy with a reasonable safety profile for patients with CLL. © 1998 by The American Society of Hematology.
    Print ISSN: 0006-4971
    Electronic ISSN: 1528-0020
    Topics: Biology , Medicine
    Published by American Society of Hematology
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...